TABLE 2.
5‐Year overall survival and progression‐free survival estimates by sex in molecular subtypes of ependymoma.
| Characteristic | 5‐Year overall survival | 5‐Year progression‐free survival | |||||
|---|---|---|---|---|---|---|---|
| N | Event N | Probability (95% CI) | N | Event N | Probability (95% CI) | ||
| Total | |||||||
| Overall | 359 | 60 | 76% (71%, 82%) | 359 | 78 | 69% (63%, 76%) | |
| Predicted sex | 359 | 60 | 359 | 78 | |||
| Male | 212 | 42 | 73% (66%, 80%) | 212 | 54 | 64% (56%, 73%) | |
| Female | 147 | 18 | 82% (74%, 90%) | 147 | 24 | 76% (68%, 86%) | |
| PF‐EPN‐A | |||||||
| Overall | 199 | 48 | 67% (59%, 75%) | 199 | 57 | 60% (51%, 69%) | |
| Predicted sex | 199 | 48 | 199 | 57 | |||
| Male | 129 | 31 | 68% (59%, 78%) | 129 | 39 | 57% (47%, 69%) | |
| Female | 70 | 17 | 65% (53%, 81%) | 70 | 18 | 64% (51%, 80%) | |
| PF‐EPN‐B | |||||||
| Overall | 48 | 1 | 96% (89%, 100%) | 48 | 3 | 93% (85%, 100%) | |
| Predicted sex | 48 | 1 | 48 | 3 | |||
| Male | 19 | 0 | 100% (100%, 100%) | 19 | 1 | 94% (83%, 100%) | |
| Female | 29 | 1 | 93% (82%, 100%) | 29 | 2 | 92% (83%, 100%) | |
| PF‐SE | |||||||
| Overall | 9 | 0 | 100% (100%, 100%) | 9 | 0 | 100% (100%, 100%) | |
| Predicted sex | 9 | 0 | 9 | 0 | |||
| Male | 4 | 0 | 100% (100%, 100%) | 4 | 0 | 100% (100%, 100%) | |
| Female | 5 | 0 | 100% (100%, 100%) | 5 | 0 | 100% (100%, 100%) | |
| SP‐EPN | |||||||
| Overall | 9 | 0 | 100% (100%, 100%) | 9 | 0 | 100% (100%, 100%) | |
| Predicted sex | 9 | 0 | 9 | 0 | |||
| Male | 4 | 0 | 100% (100%, 100%) | 4 | 0 | 100% (100%, 100%) | |
| Female | 5 | 0 | 100% (100%, 100%) | 5 | 0 | 100% (100%, 100%) | |
| SP‐MPE | |||||||
| Overall | 1 | 0 | 100% (100%, 100%) | 1 | 0 | 100% (100%, 100%) | |
| Predicted sex | 1 | 0 | 1 | 0 | |||
| Male | 1 | 0 | 100% (100%, 100%) | 1 | 0 | 100% (100%, 100%) | |
| Female | 0 | NA | NA | 0 | NA | NA | |
| ST‐EPN‐RELA | |||||||
| Overall | 77 | 11 | 76% (65%, 90%) | 77 | 18 | 54% (39%, 76%) | |
| Predicted sex | 77 | 11 | 77 | 18 | |||
| Male | 49 | 11 | 63% (47%, 84%) | 49 | 14 | 51% (34%, 76%) | |
| Female | 28 | 0 | 100% (100%, 100%) | 28 | 4 | 64% (38%, 100%) | |
| ST‐EPN‐YAP1 | |||||||
| Overall | 10 | 0 | 100% (100%, 100%) | 10 | 0 | 100% (100%, 100%) | |
| Predicted sex | 10 | 0 | 10 | 0 | |||
| Male | 1 | 0 | 100% (100%, 100%) | 1 | 0 | NA | |
| Female | 9 | 0 | 100% (100%, 100%) | 9 | 0 | 100% (100%, 100%) | |
| ST‐SE | |||||||
| Overall | 6 | 0 | 100% (100%, 100%) | 6 | 0 | 100% (100%, 100%) | |
| Predicted sex | 6 | 0 | 6 | 0 | |||
| Male | 5 | 0 | 100% (100%, 100%) | 5 | 0 | 100% (100%, 100%) | |
| Female | 1 | 0 | NA | 1 | 0 | NA | |
Abbreviation: CI, confidence interval.